10月23日，三诺生物发布2025年三季报。报告显示，公司前三季度营业收入为34.53亿元，同比增长 8.52%；归母净利润为2.11亿元，同比下降17.36%；扣非归母净利润为1.80亿元，同比下降22.13%；基 本每股收益0.38元。 报告期内，三诺生物基本每股收益为0.38元，加权平均净资产收益率为6.28%。 2025年前三季度，公司毛利率为48.91%，同比下降6.32个百分点；净利率为4.42%，较上年同期下降 4.11个百分点。从单季度指标来看，2025年第三季度公司毛利率为43.29%，同比下降10.73个百分点， 环比下降11.27个百分点；净利率为-2.47%，较上年同期下降8.83个百分点，较上一季度下降10.71个百 分点。 责任编辑：小浪快报 2025年三季度，公司期间费用为15.40亿元，较上年同期增加7333.01万元；期间费用率为44.60%，较上 年同期下降1.50个百分点。其中，销售费用同比增长10.00%，管理费用同比增长8.52%，研发费用同比 减少19.49%，财务费用同比增长81.04%。 资料显示，三诺生物传感股份有限公司位于湖南省长沙高新技术产业开发区谷苑路2 ...

10月20日，三诺生物涨0.10%，成交额9206.41万元。两融数据显示，当日三诺生物获融资买入额662.10 万元，融资偿还962.86万元，融资净买入-300.76万元。截至10月20日，三诺生物融资融券余额合计4.05 亿元。 融资方面，三诺生物当日融资买入662.10万元。当前融资余额4.05亿元，占流通市值的3.77%，融资余 额超过近一年90%分位水平，处于高位。 融券方面，三诺生物10月20日融券偿还3100.00股，融券卖出400.00股，按当日收盘价计算，卖出金额 7652.00元；融券余量3.14万股，融券余额60.07万元，低于近一年10%分位水平，处于低位。 资料显示，三诺生物传感股份有限公司位于湖南省长沙高新技术产业开发区谷苑路265号，成立日期 2002年8月7日，上市日期2012年3月19日，公司主营业务涉及以生物传感技术为基础的相关慢性疾病即 时检测(POCT)产品的研发、设计、生产和销售。主营业务收入构成为：血糖监测系统73.29%，糖尿病 营养、护理等辅助产品6.59%，糖化血红蛋白检测系统5.03%，血脂检测系统4.14%，血压计4.11%， iPOCT监测系统3.94 ...

截至6月30日，三诺生物股东户数1.55万，较上期减少5.49%；人均流通股29341股，较上期增加5.81%。 2025年1月-6月，三诺生物实现营业收入22.64亿元，同比增长6.12%；归母净利润1.81亿元，同比减少 8.52%。 10月15日，三诺生物涨0.10%，成交额9200.65万元。两融数据显示，当日三诺生物获融资买入额 1037.90万元，融资偿还956.83万元，融资净买入81.07万元。截至10月15日，三诺生物融资融券余额合 计3.98亿元。 融资方面，三诺生物当日融资买入1037.90万元。当前融资余额3.97亿元，占流通市值的3.60%，融资余 额超过近一年90%分位水平，处于高位。 融券方面，三诺生物10月15日融券偿还0.00股，融券卖出7000.00股，按当日收盘价计算，卖出金额 13.80万元；融券余量3.14万股，融券余额61.92万元，低于近一年20%分位水平，处于低位。 资料显示，三诺生物传感股份有限公司位于湖南省长沙高新技术产业开发区谷苑路265号，成立日期 2002年8月7日，上市日期2012年3月19日，公司主营业务涉及以生物传感技术为基础的相关慢性疾病即 时 ...

7月30日，三诺生物今日收盘21.22元，下跌1.03%，滚动市盈率PE（当前股价与前四季度每股收益总和 的比值）达到37.45倍，总市值118.89亿元。 从行业市盈率排名来看，公司所处的医疗器械行业市盈率平均55.15倍，行业中值37.48倍，三诺生物排 名第75位。 最新一期业绩显示，2025年一季报，公司实现营业收入10.42亿元，同比2.76%；净利润7211.51万元， 同比-10.90%，销售毛利率48.69%。 序号股票简称PE(TTM)PE(静)市净率总市值(元)13三诺生物37.4536.443.60118.89亿行业平均 55.1550.114.80115.74亿行业中值37.4836.822.6955.61亿1九安医疗11.0711.200.87186.87亿2英科医疗 14.0715.171.25222.33亿3新华医疗15.9114.751.30101.98亿4振德医疗16.1515.221.0358.62亿5山东药玻 16.2116.261.86153.29亿6奥美医疗16.3215.991.6858.96亿7康德莱17.1917.201.4237.04亿8九强生物 17.501 ...

Group 1 - The core viewpoint of the articles highlights the performance and market position of Sanofi Biologicals in the medical device industry, particularly in blood glucose monitoring systems [1][2] - As of July 9, Sanofi Biologicals closed at 22.25 yuan, with a rolling PE ratio of 39.55 times and a total market capitalization of 12.555 billion yuan [1] - The average PE ratio for the medical device industry is 51.36 times, with a median of 37.22 times, placing Sanofi Biologicals at the 81st position in the industry ranking [1][2] Group 2 - As of the first quarter of 2025, 23 institutions hold shares in Sanofi Biologicals, including 21 funds, with a total holding of 97.2415 million shares valued at 2.313 billion yuan [1] - The main business of Sanofi Biologicals is the production and sale of blood glucose monitoring systems, along with related products such as diabetes nutrition and care products, blood lipid testing systems, and blood pressure monitors [1] - In the latest financial report for the first quarter of 2025, the company achieved an operating income of 1.042 billion yuan, a year-on-year increase of 2.76%, and a net profit of 72.1151 million yuan, a year-on-year decrease of 10.90%, with a gross profit margin of 48.69% [1]

Core Viewpoint - The company reported a steady revenue growth in 2024, with a total revenue of 4.443 billion yuan, representing a year-on-year increase of 9.47%, and a net profit attributable to shareholders of 326 million yuan, up 14.73% year-on-year [1][2] Revenue Performance - In 2024, the company achieved a revenue of 4.443 billion yuan, with a quarterly revenue of 1.261 billion yuan in Q4, showing a significant year-on-year growth of 23.22% [1][2] - The company’s revenue growth was driven by stable traditional business and rapid growth in new business segments [2] Profitability Metrics - The company reported a gross profit margin of 54.88% in 2024, an increase of 0.82 percentage points year-on-year [2] - The net profit attributable to shareholders for Q4 reached 70.95 million yuan, a remarkable increase of 310.96% year-on-year [1] Government Subsidies Impact - The slower growth in the non-recurring profit segment was primarily due to government subsidies amounting to 37.73 million yuan, which increased by 22.96 million yuan year-on-year [2] Regional Revenue Breakdown - Domestic revenue reached 2.578 billion yuan, up 9.81% year-on-year, while revenue from the U.S. was 1.38 billion yuan, down 2.68% [3] - Revenue from other regions saw a significant increase of 65.51%, totaling 485 million yuan [3] Product Revenue Performance - The blood glucose monitoring system generated revenue of 3.321 billion yuan, a year-on-year increase of 15.58%, accounting for 74.73% of total revenue [4] - The iPOCT monitoring system also showed growth, with revenue of 186 million yuan, up 9.11% year-on-year [4] Future Outlook - The company aims to achieve a revenue target of 4.9 billion yuan in 2025, with a steady growth in both revenue and operating profit anticipated [2] - Revenue projections for 2025-2027 are estimated at 4.926 billion, 5.483 billion, and 6.125 billion yuan, with respective year-on-year growth rates of 10.9%, 11.3%, and 11.7% [4]